Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker Corporation (Nasdaq: BRKR) has launched the NeuraLight 3D Ultra module, enhancing its Ultima multiphoton microscopes for advanced neuroscience and optogenetics research. This module features 3D holographic photostimulation, a larger liquid crystal chip for improved targeting, and a speed of 600 hologram frames per second. It allows researchers to study neural networks more effectively. The NeuraLight 3D Ultra is compatible with newer and selected older Ultima models, promoting innovation in neuroscience research.
Bruker Corporation (Nasdaq: BRKR) showcased innovations at the 70th ASMS Conference, unveiling advancements in spatial multiomics for tissue and tumor microenvironments. The MALDI HiPLEX-IHC technology integrates protein expression profiling with small molecule imaging, enhancing high-plex protein mapping and metabolic process elucidation.
The new microGRID module for the timsTOF fleX platform and SCiLS Lab 2023a software improvements facilitate virtually artifact-free imaging and advanced analytics, positioning Bruker at the forefront of cancer research innovation.
Bruker Corporation has unveiled the timsTOF HT system at the 70th ASMS meeting, enhancing its 4D Multiomics platform with a fourth-generation TIMS XR cell and a 14-bit digitizer. This innovation boosts dynamic range and peptide coverage, enabling the identification of over 100,000 unique peptides with high quantification accuracy. The system supports high-throughput proteomics, achieving sample processing rates of up to 200 samples per day. Additionally, the PaSER mode allows real-time data streaming for intelligent acquisition, further advancing metabolomics and biomarker discovery.
Bruker Corporation (NASDAQ: BRKR) has expanded its mass spectrometry capabilities by acquiring IonSense, the developer of DART™ technology, enhancing Point-of-Need (PoN) analysis. The newly launched DART-EVOQ® triple quadrupole mass spectrometer allows quick analyses across various sectors like food, forensics, and pharmaceuticals without the need for chromatography. Additionally, Bruker has partnered with TOFWERK AG to accelerate the development of high-speed analytical solutions. These strategic moves aim to position Bruker as a leader in PoN mass spectrometry.
Bruker Corporation (Nasdaq: BRKR) will present at the Jefferies 2022 Global Healthcare Conference in New York on June 9, 2022, at 3:00 pm EDT. Frank Laukien, CEO, and Justin Ward, Sr. Director of Investor Relations, will represent the company. A live audio webcast will be available on the Investor Relations section of Bruker's website, with a replay accessible for 30 days post-event. Bruker is dedicated to advancing scientific discovery and enhancing human life through its innovative analytical solutions and high-performance scientific instruments.
Bruker Corporation (NASDAQ: BRKR) announced the approval of a quarterly cash dividend of
Bruker is dedicated to advancing scientific discovery through high-performance instruments and analytical solutions that enhance human life quality. The company operates in various domains including life sciences, applied markets, and industrial applications.
Bruker Corporation (BRKR) has entered a strategic partnership with TOFWERK AG, including a minority investment by Bruker in TOFWERK. This collaboration focuses on enhancing high-speed and ultra-sensitive analytical solutions, particularly in mass spectrometry for small molecules and volatile compounds. The partnership aims to leverage Bruker’s commercial scale to boost TOFWERK’s market presence. Innovations include advanced instrument capabilities and applications for ambient air analysis, breath diagnostics, and semiconductor monitoring.
Summary not available.
Bruker Corporation reported Q1 2022 revenues of $595.0 million, a 7.3% year-over-year increase. Organic revenue growth was notable at 10.5%. The company saw GAAP diluted EPS rise to $0.41, up from $0.37 in Q1 2021. With strong demand for its life science tools, Bruker raised its FY 2022 organic revenue outlook to 7% to 9% and expects non-GAAP EPS between $2.29 to $2.33, reflecting a 9% to 11% increase year-over-year. The firm also made key acquisitions to bolster growth.
Bruker recently showcased its innovative Ascend Evo 1.0 GHz NMR magnet at the Experimental Nuclear Magnetic Resonance Conference, designed to operate at 4.2 Kelvin for structural biology in standard labs. This new technology boasts a significant reduction in liquid helium consumption by threefold, enhancing accessibility for researchers. Additionally, Bruker introduced the Heliosmart Recovery system which enables the collection of helium gas boil-off, achieving recovery rates of 80%-85%. The company continues to offer services like LabScape Remote Monitoring for effective management of NMR magnets.
FAQ
What is the current stock price of Bruker (BRKR)?
What is the market cap of Bruker (BRKR)?
